Clinical pharmacology of itraconazole in children and adolescents

Efi Drogouti; Zoe Dorothea Pana; Athanasios Tragiannidis; Georg Hempel; Andeas Groll

doi:10.1007/s12281-015-0218-1

Clinical pharmacology of itraconazole in children and adolescents

Efi Drogouti
, Zoe Dorothea Pana
, Athanasios Tragiannidis
, Georg Hempel
, Andeas Groll

Research output: Contribution to journal › Article › peer-review

Abstract

Invasive fungal infections are recognized as lifethreatening complications primarily in immunocompromised patients, including children with primary immunodeficiencies and hematological malignancies. The antifungal triazoles have become extremely useful components of the antifungal armamentarium. They are well tolerated and possess a broad spectrum of activity. Itraconazole was discovered in 1984 and became available for clinical use in 1990. Itraconazole is a broad spectrum, triazole antifungal agent, and class II drug molecule with low solubility and high permeability and several indications in adults. This article provides a brief overview of the pharmacology of itraconazole with focus on the available data in immunocompromised children and adolescents.

Original language	English
Article number	A002
Pages (from-to)	65-73
Number of pages	9
Journal	Current Fungal Infection Reports
Volume	9
Issue number	2
DOIs	https://doi.org/10.1007/s12281-015-0218-1
Publication status	Published - 1 Jun 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Children
Itraconazole
Pharmacology
Triazoles

Access to Document

10.1007/s12281-015-0218-1

Cite this

@article{774d4224f7bf484d9cce7954a05afa48,

title = "Clinical pharmacology of itraconazole in children and adolescents",

abstract = "Invasive fungal infections are recognized as lifethreatening complications primarily in immunocompromised patients, including children with primary immunodeficiencies and hematological malignancies. The antifungal triazoles have become extremely useful components of the antifungal armamentarium. They are well tolerated and possess a broad spectrum of activity. Itraconazole was discovered in 1984 and became available for clinical use in 1990. Itraconazole is a broad spectrum, triazole antifungal agent, and class II drug molecule with low solubility and high permeability and several indications in adults. This article provides a brief overview of the pharmacology of itraconazole with focus on the available data in immunocompromised children and adolescents.",

keywords = "Children, Itraconazole, Pharmacology, Triazoles",

author = "Efi Drogouti and Pana, \{Zoe Dorothea\} and Athanasios Tragiannidis and Georg Hempel and Andeas Groll",

note = "Publisher Copyright: {\textcopyright} Springer Science+Business Media New York 2015.",

year = "2015",

month = jun,

day = "1",

doi = "10.1007/s12281-015-0218-1",

language = "English",

volume = "9",

pages = "65--73",

journal = "Current Fungal Infection Reports",

issn = "1936-3761",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Clinical pharmacology of itraconazole in children and adolescents

AU - Drogouti, Efi

AU - Pana, Zoe Dorothea

AU - Tragiannidis, Athanasios

AU - Hempel, Georg

AU - Groll, Andeas

N1 - Publisher Copyright: © Springer Science+Business Media New York 2015.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Invasive fungal infections are recognized as lifethreatening complications primarily in immunocompromised patients, including children with primary immunodeficiencies and hematological malignancies. The antifungal triazoles have become extremely useful components of the antifungal armamentarium. They are well tolerated and possess a broad spectrum of activity. Itraconazole was discovered in 1984 and became available for clinical use in 1990. Itraconazole is a broad spectrum, triazole antifungal agent, and class II drug molecule with low solubility and high permeability and several indications in adults. This article provides a brief overview of the pharmacology of itraconazole with focus on the available data in immunocompromised children and adolescents.

AB - Invasive fungal infections are recognized as lifethreatening complications primarily in immunocompromised patients, including children with primary immunodeficiencies and hematological malignancies. The antifungal triazoles have become extremely useful components of the antifungal armamentarium. They are well tolerated and possess a broad spectrum of activity. Itraconazole was discovered in 1984 and became available for clinical use in 1990. Itraconazole is a broad spectrum, triazole antifungal agent, and class II drug molecule with low solubility and high permeability and several indications in adults. This article provides a brief overview of the pharmacology of itraconazole with focus on the available data in immunocompromised children and adolescents.

KW - Children

KW - Itraconazole

KW - Pharmacology

KW - Triazoles

UR - https://www.scopus.com/pages/publications/84943357965

U2 - 10.1007/s12281-015-0218-1

DO - 10.1007/s12281-015-0218-1

M3 - Article

AN - SCOPUS:84943357965

SN - 1936-3761

VL - 9

SP - 65

EP - 73

JO - Current Fungal Infection Reports

JF - Current Fungal Infection Reports

IS - 2

M1 - A002

ER -

Clinical pharmacology of itraconazole in children and adolescents

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this